Monthly News Roundup - November 2025

Keytruda & Keytruda Qlex Approved for Cisplatin-Ineligible Bladder Cancer
The U.S. Food and Drug Administration (FDA) has approved Merck’s Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each...